The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response and lymphocyte function in patients with type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 103, Issue 3, 2014, Pages 395-401

  Van Poppel, P C M ^a   Gresnigt, M S ^a   Smits, P ^a   Netea, M G ^a   Tack, C J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

DPP 4 inhibitor; Immune function; Side effects; Type 2 diabetes

Indexed keywords

DPP-4 INHIBITOR; IMMUNE FUNCTION; SIDE EFFECTS; TYPE 2 DIABETES;

ACARBOSE; ADAMANTANE; ADULT; AGED; CELLS, CULTURED; CROSS-OVER STUDIES; CYTOKINES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; MALE; MIDDLE AGED; NITRILES; PYRROLIDINES;

EID: 84898917176     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2013.12.039     Document Type: Article

References (18)

1. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
2. De Meester I., Scharpe S., Lambeir A.M. Dipeptidyl peptidases and related proteins: multifaceted markers and therapeutic targets. Clin Chem Lab Med 2009, 47:245-247.
3. Gorrell M.D., Gysbers V., McCaughan G.W. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 2001, 54:249-264.
4. Mentlein R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 1999, 85:9-24.
5. Amori R.E., Lau J., Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. J Am Med Assoc 2007, 298:194-206.
6. Richter B., Bandeira-Echtler E., Bergerhoff K., Lerch C. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 2008, 4:753-768.
7. Williams-Herman D., Engel S.S., Round E., Johnson J., Golm G.T., Guo H., et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010, 10:7.
8. van Poppel P.C., Netea M.G., Smits P., Tack C.J. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care 2011, 34:2072-2077.
9. He Y.L., Serra D., Wang Y., Campestrini J., Riviere G.J., Deacon C.F., et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet 2007, 46:577-588.
10. He Y.L. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet 2012, 51:147-162.
11. Reinhold D., Bank U., Buhling F., Tager M., Born I., Faust J., et al. Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) induces secretion of transforming growth factor-beta 1 (TGF-beta 1) in stimulated mouse splenocytes and thymocytes. Immunol Lett 1997, 58:29-35.
12. Reinhold D., Bank U., Buhling F., Lendeckel U., Faust J., Neubert K., et al. Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells. Immunology 1997, 91:354-360.
13. Lankas G.R., Leiting B., Roy R.S., Eiermann G.J., Beconi M.G., Biftu T., et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005, 54:2988-2994.
14. Vora K.A., Porter G., Peng R., Cui Y., Pryor K., Eiermann G., et al. Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses. BMC Immunol 2009, 10:19.
15. White P.C., Chamberlain-Shea H., de la Morena M.T. Sitagliptin treatment of patients with type 2 diabetes does not affect CD4+ T-cell activation. J Diabetes Complications 2010, 24:209-213.
16. Satoh-Asahara N., Sasaki Y., Wada H., Tochiya M., Iguchi A., Nakagawachi R., et al. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism 2013, 62:347-351.
17. Derosa G., Maffioli P., Ferrari I., Fogari E., D'Angelo A., Palumbo I., et al. Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. Eur J Pharmacol 2011, 651:240-250.
18. Belle L.P., Bitencourt P.E., de Bona K.S., Zanette R.A., Moresco R.N., Moretto M.B. Expression of CD26 and its association with dipeptidyl peptidase IV activity in lymphocytes of type 2 diabetes patients. Cell Biochem Biophys 2011, 61:297-302.